{"doi":"10.17615/cfm2-vw17","title":"Vasodilator Hydralazine Promotes Nanoparticle Penetration in Advanced Desmoplastic Tumors","abstract":"Desmoplastic tumors are normally resistant to nanoparticle-based chemotherapy due to dense stroma and limited particle permeability inside the tumor. Herein, we reported that hydralazine (HDZ)- A n antihypertension vasodilator-would dramatically promote nanoparticle penetration in advanced desmoplastic tumors. First, a HDZ-liposome system was developed for tumor-selective delivery of HDZ. After three injections of HDZ-liposomes at a dose of 15 mg/kg, the tumor stroma was remarkably reduced, along with ameliorated tumor hypoxia in murine models of desmoplastic melanoma (BPD6). Furthermore, HDZ-liposome treatment altered the immunosuppressive tumor microenvironment, which provided opportunities for applying this therapeutic system to aid immunotherapy in desmoplastic tumors. Using DiD-loaded liposome as a model nanoparticle, we showed that HDZ-liposome treatment significantly increased nanoparticle accumulation and penetration inside desmoplastic tumors. As a result, one single injection of doxorubicin-liposomes at a dose of 5 mg/kg resulted in strong tumor inhibition effect after HDZ-liposome pretreatment in the advanced desmoplastic melanoma with sizes over 400 mm3. Because HDZ is a widely used antihypertension drug, the findings here should be readily translatable for clinical benefits.","journal":"Carolina Digital Repository (University of North Carolina at Chapel Hill)","year":2024,"id":475187,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9514,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":650101,"name":"Lei Shen","orcid":"0000-0003-4040-8716","position":1,"is_corresponding":false},{"id":1312009,"name":"Yi‐Rong Liu","orcid":"0000-0003-4019-6901","position":2,"is_corresponding":false},{"id":1312010,"name":"Mengbo Hu","orcid":"0000-0001-7625-2026","position":3,"is_corresponding":false},{"id":1312011,"name":"Qiankun Liu","orcid":"0000-0002-2013-1310","position":4,"is_corresponding":false},{"id":1312012,"name":"Yuan Chen","orcid":"0009-0006-2917-1323","position":5,"is_corresponding":false},{"id":289627,"name":"Lan Huang","orcid":"0000-0002-3140-4687","position":6,"is_corresponding":false},{"id":457274,"name":"Wenxia Song","orcid":"0000-0001-8795-8657","position":7,"is_corresponding":false},{"id":1312008,"name":"Neng Qiu","orcid":"0000-0002-5630-4447","position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T02:06:16.992586Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}